Effect of Terlipressin on the Incidence of Early Postoperative Acute Kidney Injury in Liver Transplantation Patients

What Was Tested

This registered phase 4 trial tested Terlipressin.

The goal of this clinical trial is to evaluate the effect of intraoperative terlipressin on the incidence of early postoperative acute kidney injury in deceased doner liver transplantation.

Patients were randomly divided into experimental group and control group by numerical randomization table.

The experimental group was injected with terlipressin perioperative and the control group was injected with placebo.

It had two arms (groups): experimental group (experimental) and control group (placebo comparator).

The registry classes the interventions as drug.

More on the Plan

Acute kidney injury is a relatively common complication in patients with liver transplantation.

Who Took Part

104 actual participants took part.

It was open to people of any sex aged from 18 years up to 70 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Written informed consent provided by the patient or the patient's legally authorized representative.

The full record lists 2 inclusion and 7 exclusion criteria; among the exclusions: patients undergoing autologous liver transplantation or combined organ transplantation; patients with lower-extremity arterial stenosis; patients with severe cardiac, pulmonary, or renal disease.

How the Study Was Run

It was run as a randomized, parallel-group and double-blind study.

The participants were allocated by chance, so the Terlipressin group and the comparison group should start out alike.

The Terlipressin group and the comparison group ran side by side rather than switching.

Blinding on both sides kept the participants and researchers unaware of who received Terlipressin.

Those kept unaware of assignments: participant and care provider.

It started in 2023-10-25 with completion listed for 2024-11-08.

It ran at 1 site in China.

Its stated primary purpose is treatment.

What Was Measured

Primary outcome: Incidence of acute kidney injury after liver transplantation (time frame: in 7 days).

What This Means in Plain Language

Put simply, this is a phase 4, randomized trial of Terlipressin in 104 people.

The trial is marked completed; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Terlipressin compound page, all human trials.